Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With Diarrhea
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, double-blind, randomized, 3-arm, placebo-controlled study to evaluate the
efficacy and describe the safety of DT01 tablets in adults with IBS-D.
Patients who meet all entry criteria will be randomized to receive DT tablets or placebo or
both for 8 weeks. The study drug will be taken three times daily. Investigators will conduct
phone-based assessments on Days 7, 14, 21, 28, 35, 42, 49. Patients will return to the clinic
after dosing has completed (Day 56) for a follow-up visit.
Phase:
Phase 2
Details
Lead Sponsor:
Centre of Clinical Pharmacology, Hanoi Medical University